Making practical sense of clinical trial data in decreasing cardiovascular risk.
Clinical studies now affirm what epidemiologic evidence has long suggested-that a broad range of patients can benefit from lipid reduction, including those without overt coronary artery disease and only moderate lipid elevations. Together, these studies suggest that current goals for cholesterol reduction may not be sufficiently stringent to slow the epidemic of heart disease in this country and that aggressive lipid lowering may be just what the doctor should order.
Castelli
W P
WP
Framingham Cardiovascular Institute, Framingham, Massachusetts 01702, USA. w_castelli@msn.com
D000818:Animals; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000517:prevention & control*; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
D000960:Hypolipidemic Agents; D002784:Cholesterol